| Literature DB >> 34140485 |
Annika Bendes1, Matilda Dale1, Cecilia Mattsson1, Niclas Roxhed2,3, Leo Hanke4, Tea Dodig-Crnković1, Murray Christian4, Birthe Meineke5,6, Simon Elsässer5,6, Juni Andréll7, Sebastian Havervall8, Charlotte Thålin8, Carina Eklund9, Joakim Dillner9, Olof Beck10, Cecilia E Thomas1, Gerald McInerney4, Mun-Gwan Hong1, Ben Murrell4, Claudia Fredolini1, Jochen M Schwenk11.
Abstract
Serological testing is essential to curb the consequences of the COVID-19 pandemic. However, most assays are still limited to single analytes and samples collected within healthcare. Thus, we establish a multianalyte and multiplexed approach to reliably profile IgG and IgM levels against several versions of SARS-CoV-2 proteins (S, RBD, N) in home-sampled dried blood spots (DBS). We analyse DBS collected during spring of 2020 from 878 random and undiagnosed individuals from the population in Stockholm, Sweden, and use classification approaches to estimate an accumulated seroprevalence of 12.5% (95% CI: 10.3%-14.7%). This includes 5.4% of the samples being IgG+IgM+ against several SARS-CoV-2 proteins, as well as 2.1% being IgG-IgM+ and 5.0% being IgG+IgM- for the virus' S protein. Subjects classified as IgG+ for several SARS-CoV-2 proteins report influenza-like symptoms more frequently than those being IgG+ for only the S protein (OR = 6.1; p < 0.001). Among all seropositive cases, 30% are asymptomatic. Our strategy enables an accurate individual-level and multiplexed assessment of antibodies in home-sampled blood, assisting our understanding about the undiagnosed seroprevalence and diversity of the immune response against the coronavirus.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34140485 DOI： 10.1038/s41467-021-23893-4
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919